Literature DB >> 19365159

Chemotherapy-induced diarrhoea.

Rachel J Gibson1, Andrea M Stringer.   

Abstract

PURPOSE OF REVIEW: Diarrhoea is a major manifestation of chemotherapy-induced mucositis that until recently has received very little attention. To date, there is no detailed understanding of the underlying mechanisms of the condition. The purpose of this review is to examine the plethora of recent studies, both in the laboratory and in the clinic, which have attempted to elucidate effective treatment options. RECENT
FINDINGS: Over recent years, there have been many new treatment options trialled for ameliorating chemotherapy-induced diarrhoea. Some of these have shown great promise in small clinical studies and now need to be investigated in larger trials. Furthermore, there have been developments in the understanding of the underlying mechanisms of chemotherapy-induced diarrhoea. These developments may also lead to effective treatment options.
SUMMARY: Here, we describe the current thinking behind the mechanisms of chemotherapy-induced diarrhoea and present current and new treatment options. This opinion article highlights the shift towards more effective research into diarrhoea caused by chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19365159     DOI: 10.1097/SPC.0b013e32832531bb

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  18 in total

1.  Evaluating the patient with diarrhea: a case-based approach.

Authors:  Seth Sweetser
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

2.  Advances in understanding and improving gastrointestinal symptoms during supportive and palliative care: a decade of progress.

Authors:  Matthew A Ciorba
Journal:  Curr Opin Support Palliat Care       Date:  2016-06       Impact factor: 2.302

3.  The weaned pig as a model for Doxorubicin-induced mucositis.

Authors:  Jamee Martin; Scott C Howard; Asha Pillai; Peter Vogel; Anjaparavanda P Naren; Steven Davis; Karen Ringwald-Smith; Karyl Buddington; Randal K Buddington
Journal:  Chemotherapy       Date:  2014-10-21       Impact factor: 2.544

Review 4.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

Review 5.  Drug-induced secretory diarrhea: A role for CFTR.

Authors:  Changsuk Moon; Weiqiang Zhang; Nambirajan Sundaram; Sunitha Yarlagadda; Vadde Sudhakar Reddy; Kavisha Arora; Michael A Helmrath; Anjaparavanda P Naren
Journal:  Pharmacol Res       Date:  2015-09-30       Impact factor: 7.658

6.  Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

Authors:  Alexander Stein; Wieland Voigt; Karin Jordan
Journal:  Ther Adv Med Oncol       Date:  2010-01       Impact factor: 8.168

Review 7.  Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review.

Authors:  Raja Nur Firzanah Syaza Raja Sharin; Jesmine Khan; Mohamad Johari Ibahim; Mudiana Muhamad; Joanne Bowen; Wan Nor I'zzah Wan Mohamad Zain
Journal:  Biomed Res Int       Date:  2022-06-28       Impact factor: 3.246

Review 8.  Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics.

Authors:  Ysabella Z A Van Sebille; Romany Stansborough; Hannah R Wardill; Emma Bateman; Rachel J Gibson; Dorothy M Keefe
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

9.  Pien Tze Huang alleviates 5-fluorouracil-induced intestinal mucositis in CT-26 tumor-bearing mice.

Authors:  Caixuan Fu; Jianfeng Chu; Aling Shen; Liya Liu; Hongwei Chen; Jiumao Lin; Thomas J Sferra; Youqin Chen; Jun Peng
Journal:  Exp Ther Med       Date:  2017-07-10       Impact factor: 2.447

10.  Effects of Continuing Adjuvant S-1 for 1 Year on the Prognosis of Gastric Cancer Patients: Results from a Prospective Single Center Study.

Authors:  Hasu Eun; Hoon Hur; Cheul Soo Byun; Sang-Yong Son; Sang-Uk Han; Yong Kwan Cho
Journal:  J Gastric Cancer       Date:  2015-06-30       Impact factor: 3.720

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.